Powering Discovery through Target Evaluation | Tables and Figures

ORDER NOW

ORDER NOW!

Print
$2,750.00

Single-site or operational unit license
$3,500.00

Country license
$4,200.00

Country or Global license
Contact David Cunningham,
Account Manager,
781-972-5472
cunningham@
healthtech.com

Length
114 pages

Date published
August 2005

Additional info
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

Powering Discovery through Target Evaluation:
Moving Beyond the Validation Paradigm

By Allan B. Haberman, Ph.D., Haberman Associates, The Biopharmaceutical Consortium

New Page 1

Figure 2.1. Pharma's Use of RNAi Is Accelerating

Figure 2.2. Proportion of Projects That Currently Use RNAi, by Application

Figure 3.1. The Akt Pathway and the Use of Forkhead Translocation in Whole-Pathway Monitoring

Figure 6.1. Large-Scale Technology-Driven Drug Discovery

Figure 6.2. Biology-Driven Drug Discovery

Table 1.1. Stages of Target Evaluation as Typically Defined by Drug Discovery Researchers

Table 2.1. Target Identification Technologies

Table 2.2. Target Characterization Technologies

Table 2.3. Target Validation Technologies

Table 6.1. Selected Marketed and Pipeline Small-Molecule Drugs from Biology-Driven R&D Programs

Table 6.2. Strategies for Going Beyond the “Target Validation” Paradigm to Improve the Effectiveness of Drug Discovery and Development

Table 7.1. Molecules and Other Parameters That Can Be Used as Biomarkers

About Insight Pharma Reports

How to Order

Journalist Inquiries

Corporate Librarians and Information Services Inquiries

The Insight Pharma Reports Advisory Board

Contact Insight Pharma Reports

"CHI's Insight
Pharma Reports are
a cost-effective and reliable source
of information about the markets
we serve. The cost
for us to conduct
this kind of business
research on our
own would be
prohibitive. CHI's
Insight Pharma
Reports allow us to
keep on top of
developments in
this rapidly moving
field."

--Donald N. Halbert, Ph.D., EVP of R&D, Iconix Biosciences

A division of
Cambridge
Healthtech Institute